Quoin Pharmaceuticals Ltd DRC (QNRX)

Currency in USD
4.3500
-0.1000(-2.25%)
Closed·
4.2769-0.0731(-1.68%)
·
QNRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.30004.5000
52 wk Range
3.250041.8000
Key Statistics
Prev. Close
4.35
Open
4.3794
Day's Range
4.3-4.5
52 wk Range
3.25-41.8
Volume
9.11K
Average Volume (3m)
237.91K
1-Year Change
-39.9983%
Book Value / Share
4.86
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
QNRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
21.4000
Upside
+391.95%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 21.4000
(+391.95% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
ThinkEquity
Buy12.00+175.86%-New CoverageJun 15, 2026
Lucid Capital Markets
Buy30.00+589.66%-New CoverageMay 04, 2026

Earnings

Latest Release
May 07, 2026
EPS / Forecast
-1.77 / -1.96
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

QNRX Income Statement

Compare QNRX to Peers and Sector

Metrics to compare
QNRX
Peers
Sector
Relationship
P/E Ratio
−0.5x−2.9x−0.4x
PEG Ratio
−0.01−0.170.00
Price/Book
1.0x3.6x2.6x
Price / LTM Sales
-76.4x3.0x
Upside (Analyst Target)
267.8%244.2%51.9%
Fair Value Upside
Unlock12.1%7.2%Unlock

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company’s lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
88.75K4.55%394.95K
Other Institutional Investors
1.62M80.23%7.19M
Public Companies & Retail Investors
306.08K15.22%1.36M
Total
2.01M100.00%8.95M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Ikarian Healthcare Master Fund, L.P.10.52%211,538941
Ikarian Capital, LLC10.52%211,538941

People Also Watch

23.33
FLY
+6.58%
40.32
VIAV
+6.81%
4.5500
MNTS
+8.33%
411.13
CIEN
+5.21%
0.960
OTLK
+5.15%

FAQ

What Is the Quoin Pharmaceuticals DRC (QNRX) Stock Price Today?

The Quoin Pharmaceuticals DRC stock price today is 4.3500 USD.

What Stock Exchange Does Quoin Pharmaceuticals DRC Trade On?

Quoin Pharmaceuticals DRC is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Quoin Pharmaceuticals DRC?

The stock symbol for Quoin Pharmaceuticals DRC is "QNRX."

What Is the Quoin Pharmaceuticals DRC (QNRX) Afterhours Price Today? (Afterhours variable test: 4.2100) Current Date: Aug 05, 2026

After hours price: 4.2100. After hours price change (units): -0.1400. Price change percentage: -3.2200%

What Is the Quoin Pharmaceuticals DRC Market Cap?

As of today, Quoin Pharmaceuticals DRC market cap is 8.6400M USD.

What Is Quoin Pharmaceuticals DRC's Earnings Per Share (TTM)?

The Quoin Pharmaceuticals DRC EPS (TTM) is -10.4278.

From a Technical Analysis Perspective, Is QNRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Quoin Pharmaceuticals DRC Stock Split?

Quoin Pharmaceuticals DRC has split 3 times.

How Many Employees Does Quoin Pharmaceuticals DRC Have?

Quoin Pharmaceuticals DRC has 5 employees.

What is the current trading status of Quoin Pharmaceuticals DRC (QNRX)?

As of Aug 05, 2026, Quoin Pharmaceuticals DRC (QNRX) is trading at a price of 4.3500 USD, with a previous close of 4.3500 USD. The stock has fluctuated within a day range of 4.3000 USD to 4.5000 USD, while its 52-week range spans from 3.2500 USD to 41.8000 USD.

What Is Quoin Pharmaceuticals DRC (QNRX) Price Target According to Analysts?

The average 12-month price target for Quoin Pharmaceuticals DRC is 21.4000 USD, with a high estimate of 35 USD and a low estimate of 12 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +391.95% Upside potential.

What Is the QNRX After Hours Price?

QNRX's last after hours stock price is 4.2100 USD, the stock has decreased by -0.1400, or -3.2200%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.